公开(公告)号：MX2016002083A

公开(公告)日：2016-06-23

申请号：MX2016002083

申请日：2014-08-08

Applicant: BAXTER INT

Inventor： LEYPOLDT JOHN KENNETH ,  AKONUR ALP ,  LO YIN-CHENG ,  AGAR BARIS UGAR

IPC: G06F19/00

Abstract: Un método para predecir concentraciones de potasio en suero en un paciente durante la hemodiálisis incluye medir las concentraciones de potasio en suero del paciente durante un tiempo de la sesión de tratamiento de hemodiálisis y una tasa de ultrafiltración calculada mediante una diferencia entre el peso corporal post- y pre-dialítico del paciente durante una sesión de tratamiento de hemodiálisis dividida entre un tiempo total de tratamiento de la sesión de tratamiento y estimar una depuración de movilización del potasio y un volumen de distribución pre-diálisis del potasio para el paciente. Las concentraciones de potasio en suero del paciente pueden entonces predecirse en cualquier momento durante cualquier sesión de tratamiento de hemodiálisis con la depuración de movilización del potasio estimada y el volumen de distribución pre-diálisis del paciente.

公开(公告)号：ES2653716T3

公开(公告)日：2018-02-08

申请号：ES14755746

申请日：2014-08-08

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

Inventor： AKONUR ALP ,  LEYPOLDT JOHN KENNETH ,  LO YING CHENG ,  AGAR BARIS UGAR

IPC: G06F19/00

Abstract: Un procedimiento de predicción de concentraciones séricas de potasio en un paciente durante hemodiálisis, comprendiendo el procedimiento: medir concentraciones séricas de potasio ("C") del paciente durante un tiempo de sesión de tratamiento de hemodiálisis y una tasa de ultrafiltración ("QUF") calculada mediante una diferencia del peso corporal del paciente antes y después de la diálisis durante una sesión de tratamiento de hemodiálisis inicial dividida por un tiempo total de tratamiento de la sesión de tratamiento; estimar KM y VPRE para el paciente usando un ajuste de mínimos cuadrados no lineal para las ecuaciones:**Fórmula** en las que t es un tiempo durante la sesión de tratamiento de hemodiálisis, T es un tiempo después de un final de la sesión de tratamiento de hemodiálisis, ttx es una duración total de la sesión de tratamiento de hemodiálisis, CPRE es una concentración plasmática de potasio previa a la diálisis, CPOST es una concentración plasmática de potasio posterior a la diálisis, CD es una concentración de potasio en el dializado, KM es un aclaramiento por movilización de potasio del paciente, KR es un aclaramiento renal residual de potasio, D es una dialisancia de potasio del dializador, VPRE es un volumen de distribución de potasio previo a la diálisis del paciente, y**Fórmula** y predecir C del paciente en cualquier momento durante cualquier sesión de tratamiento de hemodiálisis usando las ecuaciones 1-A y 1-B con los KM y VPRE estimados del paciente.

公开(公告)号：AU2011239489B2

公开(公告)日：2015-04-02

申请号：AU2011239489

申请日：2011-04-15

Applicant: BAXTER HEALTHCARE SA ,  BAXTER INT

Inventor： AKONUR ALP ,  LEYPOLDT JOHN KENNETH ,  LO YING-CHENG ,  AGAR BARIS UGUR

IPC: G06F19/00 ,  A61M1/14

Abstract: A renal failure blood therapy system includes: (i) a renal failure blood therapy machine; (ii) a therapy prescription for a patient treated by the renal failure blood therapy machine to remove a solute from the patient's blood; (iii) a test including multiple blood samples taken at multiple times during a test therapy to determine concentration levels of the solute at each of the multiple times; and (iv) a device programmed to use a kinetic model for the solute in a first instance with at least one of the concentration levels of the solute to estimate at least one estimated patient parameter. The device is further programmed to enable a user to determine at least one of a therapy duration, a therapy frequency, a dialysate flowrate or a blood flowrate for the therapy prescription.

公开(公告)号：ES2717130T3

公开(公告)日：2019-06-19

申请号：ES17173110

申请日：2014-08-08

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

Inventor： AKONUR ALP ,  LEYPOLDT JOHN KENNETH ,  LO YING-CHENG ,  AGAR BARIS UGAR

公开(公告)号：CA2796505C

公开(公告)日：2018-12-11

申请号：CA2796505

申请日：2011-04-15

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

Inventor： AKONUR ALP ,  LEYPOLDT JOHN KENNETH ,  LO YING-CHENG ,  AGAR BARIS UGUR

IPC: A61M1/14 ,  A61M1/16

Abstract: A renal failure blood therapy system includes: (i) a renal failure blood therapy machine; (ii) a therapy prescription for a patient treated by the renal failure blood therapy machine to remove a solute from the patient's blood; (iii) a test including multiple blood samples taken at multiple times during a test therapy to determine concentration levels of the solute at each of the multiple times; and (iv) a device programmed to use a kinetic model for the solute in a first instance with at least one of the concentration levels of the solute to estimate at least one estimated patient parameter. The device is further programmed to enable a user to determine at least one of a therapy duration, a therapy frequency, a dialysate flowrate or a blood flowrate for the therapy prescription.

公开(公告)号：AU2015203634A1

公开(公告)日：2015-07-23

申请号：AU2015203634

申请日：2015-06-29

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

Inventor： AKONUR ALP ,  LEYPOLDT JOHN KENNETH ,  LO YING-CHENG ,  AGAR BARIS UGAR

IPC: G06F19/00 ,  A61M1/14

Abstract: A renal failure blood therapy system includes: (i) a renal failure blood therapy machine; (ii) a therapy prescription for a patient treated by the renal failure blood therapy machine to remove a solute from the patient's blood; (iii) a test including multiple blood samples taken at multiple times during a test therapy to determine concentration levels of the solute at each of the multiple times; and (iv) a device programmed to use a kinetic model for the solute in a first instance with at least one of the concentration levels of the solute to estimate at least one estimated patient parameter. The device is further programmed to enable a user to determine at least one of a therapy duration, a therapy frequency, a dialysate flowrate or a blood flowrate for the therapy prescription. 0 C) C) C)C a)A - a CO co C)D Co C -. - 2 ) ca C) CL a) ~0- I O a) d U) (D o 47----ac 0 ) ct = E :, U3 C X= 0 C)U =) I~~~E ED 0 c- L o wC IC) o z2 2 a) , U) 2) ca co ip 0- 1 C C 4 I (D I In _c CI w- c 6 (D C N - - - - - - -

公开(公告)号：AU2011239488B2

公开(公告)日：2015-05-21

申请号：AU2011239488

申请日：2011-04-15

Applicant: BAXTER HEALTHCARE SA ,  BAXTER INT

Inventor： AKONUR ALP ,  LEYPOLDT JOHN KENNETH ,  LO YING-CHENG ,  AGAR BARIS UGAR

IPC: G06F19/00

Abstract: A method of predicting serum phosphorus concentrations in a patient during hemodialysis includes measuring serum phosphorus concentrations of the patient over a hemodialysis treatment session time and an ultrafiltration rate calculated by a difference between pre- and post-dialytic body weight of the patient during an initial hemodialysis treatment session divided by a total treatment time of the treatment session and estimating a phosphorous mobilization clearance and a pre-dialysis distribution volume of phosphorus for the patient. Serum phosphorus concentrations of the patient can then be predicted at any time during any hemodialysis treatment session with the estimated phosphorous mobilization clearance and pre-dialysis distribution volume of phosphorus of the patient.

公开(公告)号：CA2796496A1

公开(公告)日：2011-10-20

申请号：CA2796496

申请日：2011-04-15

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

Inventor： AKONUR ALP ,  LEYPOLDT JOHN KENNETH ,  LO YING-CHENG ,  AGAR BARIS UGUR

IPC: G06F19/00

Abstract: A method of predicting serum phosphorus concentrations in a patient during hemodialysis includes measuring serum phosphorus concentrations of the patient over a hemodialysis treatment session time and an ultrafiltration rate calculated by a difference between pre- and post-dialytic body weight of the patient during an initial hemodialysis treatment session divided by a total treatment time of the treatment session and estimating a phosphorous mobilization clearance and a pre-dialysis distribution volume of phosphorus for the patient. Serum phosphorus concentrations of the patient can then be predicted at any time during any hemodialysis treatment session with the estimated phosphorous mobilization clearance and pre-dialysis distribution volume of phosphorus of the patient.

公开(公告)号：CA2796496C

公开(公告)日：2018-03-20

申请号：CA2796496

申请日：2011-04-15

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

Inventor： AKONUR ALP ,  LEYPOLDT JOHN KENNETH ,  LO YING-CHENG ,  AGAR BARIS UGUR

IPC: A61B5/155 ,  A61B5/145 ,  A61M1/16 ,  A61M1/34

Abstract: A method of predicting serum phosphorus concentrations in a patient during hemodialysis includes measuring serum phosphorus concentrations of the patient over a hemodialysis treatment session time and an ultrafiltration rate calculated by a difference between pre- and post-dialytic body weight of the patient during an initial hemodialysis treatment session divided by a total treatment time of the treatment session and estimating a phosphorous mobilization clearance and a pre-dialysis distribution volume of phosphorus for the patient. Serum phosphorus concentrations of the patient can then be predicted at any time during any hemodialysis treatment session with the estimated phosphorous mobilization clearance and pre-dialysis distribution volume of phosphorus of the patient.

公开(公告)号：AU2015203634C1

公开(公告)日：2018-01-25

申请号：AU2015203634

申请日：2015-06-29

Applicant: BAXTER HEALTHCARE SA ,  BAXTER INT

Inventor： AKONUR ALP ,  LEYPOLDT JOHN KENNETH ,  LO YING-CHENG ,  AGAR BARIS UGAR

IPC: G06F19/00 ,  A61M1/14

Abstract: A renal failure blood therapy system includes: (i) a renal failure blood therapy machine; (ii) a therapy prescription for a patient treated by the renal failure blood therapy machine to remove a solute from the patient's blood; (iii) a test including multiple blood samples taken at multiple times during a test therapy to determine concentration levels of the solute at each of the multiple times; and (iv) a device programmed to use a kinetic model for the solute in a first instance with at least one of the concentration levels of the solute to estimate at least one estimated patient parameter. The device is further programmed to enable a user to determine at least one of a therapy duration, a therapy frequency, a dialysate flowrate or a blood flowrate for the therapy prescription. 0 C) C) C)C a)A - a CO co C)D Co C -. - 2 ) ca C) CL a) ~0- I O a) d U) (D o 47----ac 0 ) ct = E :, U3 C X= 0 C)U =) I~~~E ED 0 c- L o wC IC) o z2 2 a) , U) 2) ca co ip 0- 1 C C 4 I (D I In _c CI w- c 6 (D C N - - - - - - -